Invst LLC Invests $57,000 in Immix Biopharma, Inc. (NASDAQ:IMMX)

Invst LLC purchased a new stake in shares of Immix Biopharma, Inc. (NASDAQ:IMMX) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 27,000 shares of the company’s stock, valued at approximately $57,000. Invst LLC owned approximately 0.10% of Immix Biopharma at the end of the most recent reporting period.

Separately, Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock valued at $116,000 after purchasing an additional 17,800 shares during the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Price Performance

IMMX opened at $1.48 on Wednesday. Immix Biopharma, Inc. has a fifty-two week low of $1.43 and a fifty-two week high of $7.75. The company has a market cap of $39.09 million, a price-to-earnings ratio of -1.59 and a beta of 0.17. The firm has a 50 day simple moving average of $1.97 and a 200 day simple moving average of $2.21.

Immix Biopharma (NASDAQ:IMMX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. As a group, analysts expect that Immix Biopharma, Inc. will post -0.64 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a report on Monday, August 19th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.